RAD51 and neoplasm: A significantly better tumor reduction and longer PFS was observed in MRE11- and RAD51-negative cases compared with MRE11 or RAD51 positive cases, suggesting that inhibition of these two main HR actors could improve sensitivity to chemotherapy [97].